Literature DB >> 7363403

The clinical evaluation of analogs--III. Anthracyclines.

S K Carter.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7363403     DOI： 10.1007/bf00255451

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  7 in total

1.  Adriamycin-a review.

Authors:  S K Carter
Journal:  J Natl Cancer Inst       Date:  1975-12       Impact factor: 13.506

2.  Phase I clinical trials.

Authors:  S K Carter; O Selawry; M Slavik
Journal:  Natl Cancer Inst Monogr       Date:  1977-03

Review 3.  Adriamycin. A new anticancer drug with significant clinical activity.

Authors:  R H Blum; S K Carter
Journal:  Ann Intern Med       Date:  1974-02       Impact factor: 25.391

4.  Cardiotoxicity of adriamycin and related anthracyclines.

Authors:  L Lenaz; J A Page
Journal:  Cancer Treat Rev       Date:  1976-09       Impact factor: 12.111

5.  Adriamycin cardiotoxicity: endomyocardial biopsy evidence of enhancement by irradiation.

Authors:  M E Billingham; M R Bristow; E Glatstein; J W Mason; M A Masek; J R Daniels
Journal:  Am J Surg Pathol       Date:  1977-03       Impact factor: 6.394

6.  Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization.

Authors:  M R Bristow; J W Mason; M E Billingham; J R Daniels
Journal:  Ann Intern Med       Date:  1978-02       Impact factor: 25.391

7.  Quantitative prediction of drug toxicity in humans from toxicology in small and large animals.

Authors:  M A Goldsmith; M Slavik; S K Carter
Journal:  Cancer Res       Date:  1975-05       Impact factor: 12.701
  7 in total
  6 in total

1.  Treatment of acute leukemia and malignant lymphoma with (2"R)-4'-O-tetrahydropyranyladriamycin.

Authors:  R Ohno; K Kimura; I Amaki; M Hirano; A Hoshino; Y Ikeda; I Kimura; M Kobayashi; K Konno; H Majima
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

2.  Effect of amrinone on anthracycline-induced lethal and cardiac toxicity in mice and rats.

Authors:  F Villani; C Manzotti; M Mella; E Monti; G Savi; F Zunino
Journal:  Med Oncol Tumor Pharmacother       Date:  1990

3.  Phase I study of 4-demethoxydaunorubicin.

Authors:  V Bonfante; L Ferrari; F Villani; G Bonadonna
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

4.  Mitoxantrone: propensity for free radical formation and lipid peroxidation--implications for cardiotoxicity.

Authors:  R F Novak; E D Kharasch
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

5.  Uptake and retention of morpholinyl anthracyclines by adriamycin-sensitive and -resistant P388 cells.

Authors:  D G Streeter; J S Johl; G R Gordon; J H Peters
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

6.  Pharmacokinetics of anthracyclines in dogs: evidence for structure-related body distribution and reduction to their hydroxy metabolites.

Authors:  M J Oosterbaan; R J Dirks; T B Vree; E van der Kleijn
Journal:  Pharm Res       Date:  1984-01       Impact factor: 4.200
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.